Hardware execution log demonstrating fidelity collapse at the 60% completion mark.
| Execution Phase | Qubit Allocation | V9.0 Mitigated State |
|---|---|---|
| Initialization | 98 / 156 (Protein + Drug) | 73.00% |
| Solvent Trajectory | 156 / 156 (Maxed) | 41.20% |
| Decoherence Cascade | OVERALLOCATION | 0.00% (STATE COLLAPSE) |
To accurately simulate the binding affinity of a potential cancer drug (like the zinc metallochaperone ZMC1) to a mutated target, one must simulate not only the two molecules but the water molecules separating them. In Framework V9.0, explicit representation costs qubits:
For the p53 R175H/ZMC1 complex:
With only 26 qubits available for the solvent layer, the algorithm can only model approximately 13 water molecules explicitly. A true docking process requires modeling the hydrophobic interactions of at least 80 surrounding water molecules.
When the simulation reaches the point where the drug begins to displace the solvent (t=60%), the V9.0 Compiler attempts to dynamically reallocate topological routing qubits to model the extra states. This destroys the error-correction topology, resulting in a sudden, catastrophic loss of fidelity—termed the Decoherence Cascade.
To maintain fault-tolerance while simulating the hydration shell around the binding pocket, the required quantum volume scales relative to the grid volume $V$: $$ Q_{req} \approx \frac{V \cdot \rho_{water}}{v_{molecule}} \times 2 $$ Our calculations show that a stable simulation requires $Q_{req} \ge 256$. The upcoming IBM Flamingo architecture (156-qubit modules coupled together) will be the first hardware capable of breaking this barrier.
The failure of Project NEXUS-156 is a critical scientific benchmark. It defines the absolute ceiling of the NISQ (Noisy Intermediate-Scale Quantum) era for pharmaceutical research. While we have proven we can understand the origins of life and disease (Projects 01-09) with 156 qubits, the actual design of a quantum cure in silico must await the next generation of hardware.